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AbstrAct
Objective Alcohol-related pancreatitis is 
associated with a disproportionately large number of 
hospitalisations among GI disorders. Despite its clinical 
importance, genetic susceptibility to alcoholic chronic 
pancreatitis (CP) is poorly characterised. To identify risk 
genes for alcoholic CP and to evaluate their relevance 
in non-alcoholic CP, we performed a genome-wide 
association study and functional characterisation of a 
new pancreatitis locus.
Design 1959 European alcoholic CP patients and 
population-based controls from the KORA, LIFE and INCIPE 
studies (n=4708) as well as chronic alcoholics from the 
GESGA consortium (n=1332) were screened with Illumina 
technology. For replication, three European cohorts 
comprising 1650 patients with non-alcoholic CP and 6695 
controls originating from the same countries were used.
results We replicated previously reported risk loci 
CLDN2-MORC4, CTRC, PRSS1-PRSS2 and SPINK1 in 
alcoholic CP patients. We identified CTRB1-CTRB2 
(chymotrypsin B1 and B2) as a new risk locus with lead 
single-nucleotide polymorphism (SNP) rs8055167 (OR 
1.35, 95% CI 1.23 to 1.6). We found that a 16.6 kb 
inversion in the CTRB1-CTRB2 locus was in linkage 
disequilibrium with the CP-associated SNPs and was best 
tagged by rs8048956. The association was replicated in 
three independent European non-alcoholic CP cohorts 
of 1650 patients and 6695 controls (OR 1.62, 95% CI 
1.42 to 1.86). The inversion changes the expression 
ratio of the CTRB1 and CTRB2 isoforms and thereby 
affects protective trypsinogen degradation and ultimately 
pancreatitis risk.
conclusion An inversion in the CTRB1-CTRB2 
locus modifies risk for alcoholic and non-alcoholic CP 
indicating that common pathomechanisms are involved 
in these inflammatory disorders.
IntrODuctIOn
Chronic pancreatitis (CP) is a relapsing, progres-
sive inflammatory disorder of alcoholic  (ACP), 
idiopathic or hereditary aetiology. In about half 
of non-alcoholic CP (NACP) cases, a genetic 
background has been identified with mutations in 
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table 1 Description of the cohorts included in the analysis
cohort type no. Alcohol abuse Age (range) Male sex (%)
Initial GWAS cohort
  ACP cases (Pan-European Working Group) 1959 Yes 50 (17–98) 1674 (85.5%)
  Controls (KORA, INCIPE) 2637 – 49 (25–84) 1073 (62.0%)
  Controls (GESGA and KORA) 1488 Yes 48 (26–74) 1474 (99.1%)
  Controls (KORA) 1915 No 47 (25–74) 686 (35.8%)
Replication cohort 1
  NACP cases (Pan-European Working Group) 584 No 21 (1–71) 287 (49.1%)
  Controls (LIFE) 4892 – 63 (19–82) 2379 (48.6%)
Replication cohort 2
  NACP cases (France, Brest) 546 No 18 (1–72) 281 (51.5%)
  Controls (France, Brest) 1043* – 30 (17–75) 295 (50.6%)
Replication cohort 3
  NACP cases (Germany, Greifswald) 520 No 41 (1–86) 288 (55.4%)
  Controls (Germany, Greifswald) 760 – 32 (18–68) 465 (61.0%)
Further details of cohorts are provided in online supplementary table S1.
*In the French control cohort, age and gender data were available for 583 subjects only.
ACP, alcoholic chronic pancreatitis; GWAS, genome-wide association study; No., number of individuals after quality control filtering; NACP, non-alcohol-related chronic pancreatitis.
significance of this study
What is already known on this subject?
 ► Genetic risk underlying alcoholic chronic pancreatitis 
(CP) is poorly understood. In contrast, the genetic basis 
of non-alcoholic CP has been more comprehensively 
characterised.
 ► Alcohol abuse is a predominant cause of CP; however, only 
a small percentage of alcohol abusers develop the disease, 
suggesting that genetic susceptibility may contribute to 
pathogenesis.
 ► A genome-wide association study (GWAS) reported variants 
in the PRSS1-PRSS2 and CLDN2-MORC4 loci associated with 
CP. More recent studies indicate that these variants may 
have the strongest effect in alcoholic CP.
What are the new findings?
 ► This is the largest European GWAS in patients with alcoholic 
CP. The results replicate the reported associations with 
variants in the CLDN2-MORC4, CTRC, PRSS1-PRSS2 and 
SPINK1 loci.
 ► We identified CTRB1-CTRB2 (chymotrypsin B1 and B2) 
as a new risk locus for alcoholic CP and found that a 
16.6 kb inversion in the CTRB1-CTRB2 locus was in linkage 
disequilibrium with the associated single-nucleotide 
polymorphisms. The association was replicated in 
non-alcoholic CP.
 ► The inversion changes the expression ratio of the CTRB1 and 
CTRB2 isoforms and thereby affects protective trypsinogen 
degradation and ultimately pancreatitis risk.
How might it impact on clinical practice in the foreseeable 
future?
 ► The results indicate that alcoholic and non-alcoholic CP 
share common pathomechanisms.
 ► As the same variants influence development of alcoholic 
and non-alcoholic CP, therapeutic approaches should be 
guided by disease mechanism rather than aetiology.
 ► The identified risk variants explain about 18% of the 
variance in alcoholic CP and may serve as the basis for risk 
assessment in the clinical setting.
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risk genes CTRC (chymotrypsin C), PRSS1 (serine protease 1, 
cationic trypsinogen) and SPINK1 (serine protease inhibitor 
Kazal type 1).1 Most changes in these genes increase ectopic 
intra-pancreatic activation of the digestive serine protease 
trypsin.2–5 However, the relevance of such a trypsin-depen-
dent mechanism in ACP has remained contentious as asso-
ciation with high-effect CTRC, PRSS1 and SPINK1 variants 
is absent or considerably weaker than in NACP.5 6 Similarly, 
rare PRSS1 and CPA1 (carboxypeptidase A1) variants that 
result in misfolding and endoplasmic reticulum stress are asso-
ciated with NACP but not with ACP.7 8 The so far unidenti-
fied genetic susceptibility in ACP is an intriguing observation 
as only a small percentage of alcohol abusers develop ACP, 
suggesting that factors other than alcohol may contribute to 
disease onset.9 10
Indeed, a recent genome-wide association study (GWAS) 
revealed association of common variants in the CLDN2-MORC4 
and the PRSS1-PRSS2 loci with ACP and NACP.11 These findings 
were first replicated in a large European cohort where associa-
tion was strongest in the ACP group followed by similar observa-
tions in Japanese and Indian CP cohorts.12–15 Functional studies 
indicated that the protective PRSS1 promoter variant reduces 
transcription that should result in lower intra-pancreatic tryp-
sinogen levels.16
Here, we present the largest European multicentre GWAS 
combining 1959 ACP cases from nine countries using Illumina 
chips. As controls, chronic alcoholics without CP (n=1332) 
and population-based controls (n=4708) with data on alcohol 
consumption were used (total n=6040).
MetHODs
study population
In all participating study centres, the corresponding medical 
ethical review committees approved the study. CP was defined 
by a typical clinical course with recurrent attacks or chronic pain 
and characteristic morphological changes in imaging studies as 
well as functional impairment with exocrine and/or endocrine 
insufficiency. CP was considered as ACP if alcohol consump-
tion was >60 g for females and >80 g for males per day over 
at least 2 years. The cohorts are summarised in table 1 and in 
online supplementary table S1.
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Genotyping, quality control and GWAs statistics
Genotyping was performed on Illumina BeadChip arrays (Illumina, 
San Diego, California, USA). The ACP samples of the screening 
cohort and NACP samples of replication cohort 1 were genotyped 
at the Helmholtz Center Munich (Dr P. Lichtner). The study design 
is summarised in online supplementary figure S1.
All analyses were performed using PLINK V.1.917 and R (www. 
R- project. org). Data were filtered to achieve an individual-wise 
and single-nucleotide polymorphism (SNP)-wise call rate >0.99.18 
Genotyped sex was determined in each sample from gonosomal 
data. Related individuals were excluded (pi-hat >0.185). Hetero-
zygosity outliers defined by heterozygosity more extreme than 
median ±3 IQRs and ethnic outliers according to Price et al18 with 
6 SD criterion in principal component analysis were not used for 
further analysis. Hence, the 1959 ACP samples that passed quality 
control as well as controls (n=6040) derived from different 
consortia (KORA S3/F3 Illumina Omni data set from Augsburg, 
Germany; GESGA consortia data set from Mannheim, Germany; 
INCIPE Illumina Omni data set from Verona, Italy) were included 
for further analyses.
Imputation was performed with SHAPEIT V.2 and IMPUTE 
V.2.3.0 applying the 1000Genomes reference phase 1, V. 319 
and logistic regression was applied with the first three principal 
components of the SNP data included as covariates to account 
for possible population stratification resulting in a standardised 
overall inflation factor of 1.02.20
Imputation of the 16.6 kb inversion for further analysis
Imputation of a 16.6 kb inversion21 in the CTRB1-CTRB2 
locus within the screening cohort was performed using a 
5 Mb region on chromosome 16 between 71 310 697 bp and 
76 045 524 bp including 475 SNPs overlapping between all 
cohorts and the reference. As reference panel, quality filtered 
data of HumanOmniExpress BeadChips from 227 CP patients 
with successfully genotyped inversion genotypes were used (for 
details, see online supplementary file 1). To improve accuracy, 
the IMPUTE2 parameters number of Markov chain Monte 
Carlo iterations were set to 30 and number of hidden Markov 
Model states were increased to 200.
calculation of variance of AcP
Joint variance explained by all identified loci was measured by 
calculating McFadden’s pseudo-R2. Here, we compared a logistic 
regression including the three principal components and litera-
ture SNPs rs497078, rs17107315, rs10273639, rs12688220 and 
the inversion as independent variables with a logistic regression 
model including the first three principal components only.
replication genotyping
Details of polymerase chain reactions (PCR) and melting curve 
assays used for analysis of the CTRB1-CTRB2 locus can be found 
in the online supplementary file 1. In the first replication cohort 
of the German NACP patients and controls, chip data were used 
with similar preprocessing as described (n=584 NACP patients; 
n=4892 population-based controls from LIFE, the latter were 
genotyped using Affymetrix AXIOM-CEU (Affymetrix, St. Clara, 
California, USA) genome-wide SNP array22). Thereby, imputa-
tion on 1000Genomes reference phase 1, V. 3 was performed 
for a 5 Mb region on chromosome 16 between 71 310 697 bp 
and 76 045 524 bp using 285 SNPs fulfilling quality control in 
all individuals.
Further replication in two independent NACP cohorts from 
Germany (Greifswald cohort, 520 patients, 760 controls) 
and France (Brest cohort, 546 patients, 1043 controls) was 
carried out by genotyping SNPs with the melting curve assay 
(see online supplementary table S2).
Measurement of ctrb1 and ctrb2 mrnA expression
Samples of human pancreatic cDNA prepared from pancreatic 
exocrine fractions discarded after islet isolation were kind gifts 
from Dr Sohail Husain (Children’s Hospital of Pittsburgh) and 
Dr Rajinder Dawra (University of Minnesota) or were prepared 
from discarded surgical specimens at the University of Szeged, 
Hungary. Details of the methods used are summarised in 
online supplementary file 1.
trypsinogen activation and degradation
Human cationic trypsinogen (PRSS1) and anionic trypsinogen 
(PRSS2) were produced in Escherichia coli. His-tagged forms 
of CTRB1 and CTRB2 were expressed in HEK 293 T cells and 
purified as described previously.23 24 The effect of CTRB1 and 
CTRB2 on trypsinogen was determined in autoactivation exper-
iments and degradation assays.
results
Association of AcP with loci clDn2-MOrc4, ctrc, Prss1-
Prss2 and sPInK1
We robustly confirmed the association of loci CLDN2-MORC4 
and PRSS1-PRSS2 reported in a previous GWAS.11 Our lead SNPs 
at the CLDN2-MORC4 (rs12688091) and the PRSS1-PRSS2 
locus (rs2855983) were in linkage disequilibrium (LD) with the 
previously identified lead SNPs in these loci (see online supple-
mentary table S3). Furthermore, strong association was found 
with rs545634 in CTRC and with rs146437551 in SPINK1. 
Both susceptibility genes were previously identified in candidate 
gene studies of CP.3 5 6 25–29 In line with the literature, our top 
hits at these loci were in strong LD with the most frequently 
reported SNPs; CTRC, rs497078 (c.180C>T, p.G60=) and 
SPINK1, rs17107315 (c.101A>G, p.N34S) (see online supple-
mentary table S3). Association of the lead SNPs at the four risk 
loci remained essentially unchanged when ACP patients were 
separately compared with chronic alcoholics and non-alcoholic 
controls (see online supplementary figure S2).
Association of AcP with an alcohol-dependence locus
We also observed an association when we compared ACP 
patients versus chronic alcoholics at the known alcohol-depen-
dence locus ADH1B (alcohol dehydrogenase 1B) for rs1229984 
(OR 2.49, 95% CI 1.84 to 3.39; p=1.8×10–8). This variant 
(c.143A>G, p.H48R) alters alcohol metabolism and thereby 
deters from drinking, resulting in the observed lower frequency 
among alcoholics (see online supplementary figure S3).30
novel association of AcP with the ctrb1-ctrb2 locus
We discovered a novel association signal at the CTRB1-CTRB2 
(chymotrypsin B1 and B2) locus (figure 1 and table 2 for all 
top hits) with lead SNP rs8055167 located in intron 1 of CTRB1 
(OR 1.35, 95% CI 1.23 to 1.6; p=4.2×10–9). The association 
was also observed when ACP patients were compared with alco-
holics or population-based controls (see online supplementary 
figure S2). Regional association plots for the top hits and all 
associations with p<10–5 are summarised in online supplemen-
tary figure S4 and table S4 and risk estimates for carriers of 
multiple risk alleles are shown in online supplementary figure 
S5. Here, the identified risk variants explain about 18% of the 
variance in ACP.
group.bmj.com on January 10, 2018 - Published by http://gut.bmj.com/Downloaded from 
4 Rosendahl J, et al. Gut 2017;0:1–9. doi:10.1136/gutjnl-2017-314454
Figure 1 Genome-wide association analysis of 1959 cases with alcoholic chronic pancreatitis and 6040 controls derived from population studies 
and a cohort of alcohol-dependent patients. Genome-wide significance-level threshold (p=5×10–8) is represented by the black line. Only single-
nucleotide polymorphisms that passed quality control are depicted. 
table 2 Top associated variants in the overall cohort of European alcoholic chronic pancreatitis patients
snP ID locus Gene counted allele MAF p Value Or (95% cI)
rs545634 1p36.21 CTRC A 0.12 2.8×10–22 1.83 (1.63 to 2.06)
rs146437551 5q32 SPINK1 G 0.013 3.3×10–15 3.82 (2.79 to 5.22)
rs2855983 7q34 PRSS1-PRSS2 G 0.392 5.5×10–40 1.84 (1.69 to 2.00)
rs8055167 16q23.1 CTRB1-CTRB2 C 0.28 4.2×10–9 1.35 (1.23 to 1.49)
rs12688091 Xq22.3 CLDN2-MORC4 G 0.31 9.9×10–33 2.57 (2.22 to 2.98)
Results confirmed CLDN2-MORC4, CTRC, PRSS1-PRSS2 and SPINK1 as risk loci and identified a new locus in CTRB1-CTRB2. Data on linkage disequilibrium of the variants with 
previously reported risk variants in these loci are given in online supplementary table S3.
ID, identification; MAF, minor allele frequency; SNP, single-nucleotide polymorphism.
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Identification of a complex genetic rearrangement in the 
ctrb1-ctrb2 locus associated with cP
The CTRB1-CTRB2 locus harbours complex genomic rearrange-
ment variants which include a 16.6 kb inversion (see figure 2) 
and a 584 bp deletion in CTRB2 (not shown).21 First, we 
excluded the deletion in CTRB2 as an explanation for the associ-
ation as genotyping of 289 ACP patients revealed only negligible 
LD (R²=0.12) with our lead SNP rs8055167. Subsequently, in 
order to examine whether our lead SNP is in LD with the 16.6 kb 
inversion in the CTRB1-CTRB2 locus, we genotyped 227 ACP 
patients for the inversion and found stronger LD (R2=0.50). 
By combining our genotype data on the inversion with genetic 
data from SNP chips, we successfully imputed the inversion in all 
1959 ACP and 6040 control samples (info-score of the inversion 
=0.81, correlation of imputed inversion vs measured inversion: 
R²=0.99, see online supplementary figure S6A). The major allele 
of the inversion conferred risk for ACP with a similar effect size 
as the lead SNP at this locus (OR 1.36, 95% CI 1.20 to 1.53; 
p=3.1×10–6) (figure 3). From the ACP-associated SNPs within 
the CTRB1-CTRB2 locus, rs8048956 tagged the inversion the 
best (R2=0.987) and it was therefore used as a reporter for the 
inversion in further analyses (see online supplementary figure 
S6B).
replication of the association in nAcP cohorts
To evaluate whether rs8048956 tagging the inversion also asso-
ciates with NACP, we analysed three independent cohorts of 
patients (n=1650) and controls (n=6695) from Germany and 
France (table 1 and online supplementary table S1). In all three 
cohorts, we found a significant association and the combined 
effect across all cohorts was OR 1.62 (95% CI 1.42 to 1.86); 
p=1.64×10–12 (see online supplementary figure S7A). On the 
other hand, association of the GWAS lead SNP rs8055167, 
which had a lower LD with the inversion, was less pronounced, 
supporting the pathogenic relevance of the inversion in NACP 
(see online supplementary figure S7B).
Functional characterisation of the genetic rearrangement in 
the ctrb1-ctrb2 locus
To investigate whether the inversion affects protein translation 
and secretion, CTRB1 and CTRB2 were expressed in HEK 
293 T cells with the two different 5′ untranslated regions and 
signal peptides of the major and minor alleles. Chymotrypsin 
levels in the conditioned media of cells transfected with these 
constructs were essentially identical, indicating that the inver-
sion has no impact on protein translation and secretion. To 
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Figure 2 Schematic illustration of the CTRB1-CTRB2 locus with the 16.6 kb inversion. The inversion breakpoints lie within the region indicated 
by the dashed lines. The genomic reference sequence corresponds to the minor allele. The locations of the lead single-nucleotide polymorphism 
(SNP) rs8055167 and the best tagging SNP rs8048956 are denoted by the empty and black diamond symbols, respectively. Genomic distances are 
not scaled. Although not shown here, in this locus CTRB2 also harbours a 584 bp deletion variant (allele frequency ~7% in German controls) that 
eliminates exon 6. CTRB1, chymotrypsin B1 gene; CTRB2, chymotrypsin B2 gene; CTRB1* and CTRB2*, hybrid CTRB1 and CTRB2 genes created by the 
inversion; E, exon.
Figure 3 Regional association plots for the CTRB1-CTRB2 locus inversion. (A) p Values (–log10) are displayed against single-nucleotide 
polymorphism (SNP) genomic position (genome build hg19). The inversion is represented by the red line, triangles are genotyped SNPs, circles are 
imputed SNPs. For calculations, all alcoholic chronic pancreatitis patients and all controls were included. (b) The OR-based regional association plot 
indicates that the association is driven by the inversion. Here ORs are represented against the genomic position.
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assess the link between the inversion and expression of CTRB1-
CTRB2, we quantified the relative mRNA expression ratio of 
the two chymotrypsins using cDNA samples obtained from 
human pancreatic tissue or acinar cells with different inversion 
genotypes. We found that the major risk allele was associated 
with higher relative CTRB1 expression while heterozygous 
carriers with one minor allele expressed higher levels of CTRB2 
(figure 4A). In accordance with our findings, data from the 
GTExPortal ( gtexportal. org) indicated that the major allele of 
rs8048956 tagging the inversion was associated with increased 
CTRB1 and decreased CTRB2 mRNA expression relative to the 
minor allele. The association of the lead SNP rs8055167 with 
CTRB1-CTRB2 expression was similar but smaller, supporting 
a causal role of the inversion in CP (see online supplementary 
figure S8).
Protective degradation of anionic trypsinogen by ctrb2
When autoactivation of human anionic trypsinogen was followed 
at pH 8.0 in 1 mM calcium in the presence of CTRB1 or CTRB2, 
final trypsin levels were reduced by both chymotrypsins with a 
more prominent effect observed with CTRB2 (figure 4B). A 
similar but less pronounced effect was seen on the autoactiva-
tion of human cationic trypsinogen (PRSS1) (not shown). The 
stronger effect of CTRB2 was also confirmed in trypsinogen 
degradation experiments. SDS-PAGE analysis with Coomassie 
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Figure 4 Expression and effect of CTRB1 and CTRB2 on trypsinogen activation and degradation. (A) Expression of CTRB1 and CTRB2 mRNA in 
the pancreas of subjects with different inversion genotypes. Expression ratios of CTRB1 and CTRB2 in pancreatic cDNA samples were determined by 
real-time polymerase chain reaction using the standard curve method. Results were displayed as box plots showing minimum, first quartile (25%), 
median, third quartile (75%), maximum and the individual values (black dots). Note that subjects carrying two copies of the major risk allele exhibit 
a significantly higher CTRB1/CTRB2 expression ratio compared with heterozygous individuals with one major and one minor allele. Significance was 
calculated with unpaired t-test. (b) Effect of CTRB1 and CTRB2 on the autoactivation of human anionic trypsinogen (PRSS2). Trypsinogen (2 µM) was 
incubated with 10 nM initial trypsin and 200 nM of the indicated chymotrypsin in 0.1 M Tris-HCl (pH 8.0), 1 mM CaCl2 and 0.05% Tween 20 (final 
concentrations) at 37°C in 100 µL final volume. At the indicated times, aliquots (2 µL) were withdrawn and trypsin activity was determined using 
150 µM N-CBZ-Gly-Pro-Arg-p-nitroanilide substrate. Rate of substrate cleavage is given in mOD/min units measured at 405 nm. Note the lower trypsin 
activity that develops in the presence of chymotrypsins indicating trypsinogen degradation during activation. Under similar conditions, CTRB1 and 
CTRB2 had a similar but much smaller effect on the autoactivation of human cationic trypsinogen (PRSS1). (c) Degradation of PRSS2 by CTRB1 and 
CTRB2. Trypsinogen (1 µM) was incubated with 200 nM of the indicated chymotrypsin and 20 nM SPINK1 trypsin inhibitor in 0.1 M Tris-HCl (pH 8.0) 
and 25 mM NaCl at 37°C. Reactions were stopped at the indicated times by precipitation of 150 µL aliquots with 10% trichloroacetic acid. Samples 
were analysed by SDS-PAGE and Coomassie Blue staining. Note the disappearance of the intact trypsinogen band in the CTRB2 incubate. Some of the 
lower bands correspond to the two chains of autolysed CTRB2. Although not shown, CTRB1 or CTRB2 did not degrade cationic trypsinogen (PRSS1) to 
a detectable extent. CTRB1, chymotrypsin B1; CTRB2, chymotrypsin B2; PRSS2, anionic trypsinogen.
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Blue staining revealed more rapid protective degradation of 
anionic trypsinogen (PRSS2) by CTRB2 relative to CTRB1 
(figure 4C). Cationic trypsinogen (PRSS1) was not degraded by 
either chymotrypsin to a detectable extent (not shown).
DIscussIOn
Chronic pancreatitis is a disease of significant morbidity and 
suffering associated with a disproportionately large number of 
hospitalisations among gastrointestinal disorders. In this largest 
study ever conducted addressing the genetic basis of CP, we iden-
tified association with a complex genetic rearrangement in the 
CTRB1-CTRB2 locus. This locus contains the two highly similar 
chymotrypsin genes transcribed in opposite directions. Both 
genes comprise seven exons and the nucleotide sequences are 
97% identical with complete identity from exons 2–6. Recently, 
Pang et al21 described a 16.6 kb inversion that exchanges the 
promoter region, exon 1 and intron 1 between CTRB1 and 
CTRB2. The major, ancestral allele was arbitrarily designated 
as the inverted allele (figure 2). At the protein level, the inver-
sion switches the signal peptides of CTRB1 and CTRB2, but 
the secreted mature proenzymes are unchanged. Furthermore, 
Pang et al21 also reported a 584 bp deletion within the major 
allele leading to early termination at the protein level. Although 
a functional consequence of the deletion or inversion was antic-
ipated, no disease association was reported so far.
The first novel association signal we discovered at the CTRB1-
CTRB2 locus was the lead SNP rs8055167 located in intron 1 
of CTRB1. This association was maintained when ACP patients 
were compared with alcoholics or population-based controls 
(see online supplementary figure S2). To understand whether the 
reported larger-scale genetic rearrangements might explain the 
association of the CTRB1-CTRB2 locus with ACP, we analysed 
LD with our top SNPs. Here, an association of the 584 bp dele-
tion was ruled out as an explanation for the association signal. 
However, the 16.6 kb inversion within the locus conferred risk 
with a similar effect size and was best tagged by rs8048956 of 
the top SNPs. We also found this association in three indepen-
dent European cohorts with non-alcohol-related CP using the 
best tagging SNP.
Functional analysis indicated that the inversion results in 
a reversal of the isoform expression ratio at the mRNA level 
which is expected to translate to a similar reversal at the protein 
level. Our previous studies demonstrated that primary cleavage 
specificity and catalytic efficiency of CTRB1 and CTRB2 are 
different, with CTRB2 being more active on most substrates.31 
Consequently, a change in the isoform expression ratio likely 
causes altered chymotrypsin activity in the pancreas.
In NACP, increased intra-pancreatic activation of trypsinogen 
(PRSS1) due to the failure of protective inhibition (SPINK1) and/
or degradation (CTRC) is an important mechanism for disease 
development. The strong association of common CTRC, PRSS1-
PRSS2 and SPINK1 locus variants in ACP indicates that this 
mechanism is also relevant for ACP. Therefore, we hypothesised 
that the altered CTRB1-CTRB2 activity profile might influence 
intra-pancreatic trypsinogen activation. Here, in autoactivation 
experiments with anionic trypsinogen, final trypsin levels were 
reduced by both chymotrypsins with more prominent degra-
dation seen with CTRB2 (see figure 4). This effect for cationic 
trypsinogen was similar but less pronounced (not shown). Taken 
together, the functional studies indicate that in carriers of the 
major CTRB1-CTRB2 risk allele impaired trypsinogen (PRSS2) 
degradation due to the altered CTRB1/CTRB2 isoform ratio 
explains the observed association with CP. The relatively small 
effect of the CTRB1-CTRB2 inversion on CP risk is consistent 
with the lesser role of PRSS2 in CP (see ref. 32).
In conclusion, our GWAS identified CTRB1-CTRB2 as a 
new risk locus for ACP and NACP. The association within the 
CTRB1-CTRB2 locus was linked to a 16.6 kb inversion that 
altered CTRB1/CTRB2 expression, thereby affecting protective 
trypsinogen degradation. Furthermore, we confirmed associ-
ation of ACP with the CLDN2-MORC4, CTRC, PRSS1-PRSS2 
and SPINK1 loci. Taken together, the identified risk variants 
explained about 18% of the variance in ACP. Our study clearly 
represents a significant and transformative advance in under-
standing the genetic basis of CP. The results underpin the prom-
inent influence of commonly occurring variants in ACP and 
demonstrate that similar disease mechanisms drive both ACP 
and NACP. Thus, development of therapeutic approaches should 
be guided by disease mechanism rather than aetiology in CP.
Accession codes
The results for all imputed variants and individual-level data are 
available from the authors on request. The genomic reference 
sequence used was NT_010498.16. Reference sequences for 
mRNA were NM_001906.4 (CTRB1) and NM_001025200.3 
(CTRB2). All reference sequences correspond to the minor 
inversion allele.
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